Evidence map›Paper›PMID 38683783›Full record

ArticlePloS one2024

Structural characterization of two nanobodies targeting the ligand-binding pocket of human Arc.

José M Godoy Muñoz, Lasse Neset, Sigurbjörn Markússon, Sarah Weber, Oda C Krokengen, Aleksi Sutinen, Eleni Christakou, Andrea J Lopez, Clive R Bramham, Petri Kursula

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

José M Godoy MuñozDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0000-0002-8913-4229
Lasse NesetDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Sigurbjörn MarkússonDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0000-0003-4364-2997
Sarah WeberDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0009-0004-8281-1428
Oda C KrokengenDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Aleksi SutinenFaculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland.ORCID 0000-0001-6704-1702
Eleni ChristakouDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Andrea J LopezDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0000-0001-8956-3931
Clive R BramhamDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Petri KursulaDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0000-0001-8529-3751
University of Bergen · NOUniversity of Oulu · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The activity-regulated cytoskeleton-associated protein (Arc) is a complex regulator of synaptic plasticity in glutamatergic neurons. Understanding its molecular function is key to elucidate the neurobiology of memory and learning, stress regulation, and multiple neurological and psychiatric diseases. The recent development of anti-Arc nanobodies has promoted the characterization of the molecular structure and function of Arc. This study aimed to validate two anti-Arc nanobodies, E5 and H11, as selective modulators of the human Arc N-lobe (Arc-NL), a domain that mediates several molecular functions of Arc through its peptide ligand binding site. The structural characteristics of recombinant Arc-NL-nanobody complexes were solved at atomic resolution using X-ray crystallography. Both anti-Arc nanobodies bind specifically to the multi-peptide binding site of Arc-NL. Isothermal titration calorimetry showed that the Arc-NL-nanobody interactions occur at nanomolar affinity, and that the nanobodies can displace a TARPγ2-derived peptide from the binding site. Thus, both anti-Arc-NL nanobodies could be used as competitive inhibitors of endogenous Arc ligands. Differences in the CDR3 loops between the two nanobodies indicate that the spectrum of short linear motifs recognized by the Arc-NL should be expanded. We provide a robust biochemical background to support the use of anti-Arc nanobodies in attempts to target Arc-dependent synaptic plasticity. Function-blocking anti-Arc nanobodies could eventually help unravel the complex neurobiology of synaptic plasticity and allow to develop diagnostic and treatment tools.

Indexed as

Cytoskeletal ProteinsNerve Tissue ProteinsSingle-Domain AntibodiesAmino Acid SequenceBinding SitesCrystallography, X-RayHumansLigandsModels, MolecularProtein Bindingactivity regulated cytoskeletal-associated proteinCytoskeletal ProteinsLigandsNerve Tissue ProteinsSingle-Domain Antibodies

Identifiers

PMID38683783
PMCPMC11057775
OpenAlexW4396215906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.